NCT04720443View on ClinicalTrials.gov

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 22, 2019

Primary Completion Date

July 14, 2022

Study Completion Date

July 14, 2022

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

NIP292 tablet

NIP292 (oral tablet at 10 mg) or placebo

DRUG

NIP292 tablet

NIP292 (oral tablet at 30 mg) or placebo

DRUG

NIP292 tablet

NIP292 (oral tablet at 100 mg) or placebo

DRUG

NIP292 tablet

NIP292 (oral tablet at 300 mg) or placebo

DRUG

NIP292 tablet

NIP292 (oral tablet at 500 mg) or placebo

DRUG

NIP292 tablets

NIP292 (oral tablet at dosage 1) or placebo

DRUG

NIP292 tablets

NIP292 (oral tablet at dosage 2) or placebo

Trial Locations (1)

91206

PAREXEL International, Glendale

All Listed Sponsors
lead

The National Institutes of Pharmaceutical R&D Co. Ltd, China

INDUSTRY

NCT04720443 - A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects | Biotech Hunter | Biotech Hunter